Information Provided By: 
Fly News Breaks for July 18, 2017
CORT
Jul 18, 2017 | 08:40 EDT
Ladenburg Thalmann analyst Christopher James raised his price target for Corcept Therapeutics to $20 after hosting investor meetings with CEO Joseph Belanoff. The company remains undervalued from its core Korlym business, which has "significant untapped growth remaining," James tells investors in a research note. Further, the analyst sees a "high probability of success" for Corcept's second generation compound, CORT125134, which has Phase 2 data approaching. He keeps a Buy rating on the shares.
News For CORT From the Last 2 Days
CORT
Apr 25, 2024 | 10:38 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
